source
- Celldex halts skin disease program after barzolvolimab fails phase 2 trialCelldex Therapeutics announced it is discontinuing development of its anti‑KIT antibody barzolvolimab for chronic skin disorders after the drug failed to meet its primary endpoint in a phase 2 stud…
- Novartis beats sales expectations as Q2 revenue rises to $14.4B, eyes upcoming study readoutsNovartis reported a modest rise in second‑quarter sales, lifting its share price after the company posted a 1% increase in net sales to $14.4 billion, surpassing analyst forecasts for a decline. A…